

# CellaVision and Sysmex Sign Strategic Alliance Agreement

CellaVision and Sysmex Corporation ("Sysmex") announces a Strategic Alliance Agreement to reinforce and extend their joint leadership position within hematology and seize new opportunities for optimized diagnostics.

For 20 years CellaVision and Sysmex have had a successful partnership, and with the Strategic Alliance Agreement the parties expand their mutual commitment until 2038. The expansion enables the companies to further streamline laboratory processes and transform the field of digital cell morphology.

Through the agreement, CellaVision and Sysmex strengthen the existing relationship by a deeper and broader collaboration within innovation and collaborative commercialization. Sysmex's leading expertise in hematology, combined with CellaVision's advanced imaging solutions and AI-assisted cell classifications, lays the groundwork for the continued innovation of state-of-the-art offerings. This will gradually expand the addressable market through a mutual commitment to raise the standard of diagnostic certainty globally.

*"We are pleased to expand our alliance with CellaVision since 2013. This alliance enables us to further enhance our leadership position in hematology worldwide. We will collaborate wider and deeper to increase value to our customers by portfolio expansion in digital cell morphology."*

- Takashi Ono, Member of the Managing Board and Senior Executive Officer, Managing Director at Sysmex Corporation.

*"This alliance marks an important milestone in our joint mission to elevate healthcare and evolve microscopy together for a better healthcare journey. We are delighted to further strengthen our ties with Sysmex to continue the global adoption of advanced digital cell morphology solutions integrated with the leading cell counter offerings of Sysmex."*

- Simon Østergaard, President & CEO, CellaVision AB.

## About Sysmex Corporation

Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in *in vitro* diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. For more information about Sysmex, please visit [www.sysmex.co.jp/en/](http://www.sysmex.co.jp/en/)

## Contact

---

Simon Østergaard  
Chief Executive Officer  
Mobil: +46 (0) 70 036 37 92  
Direct: +46 (0) 46 460 16 23

## Contact

---

Adele Horn  
Corporate Communications & Investor Relations Manager  
Tel: + 46 46 460 26 04  
[www.cellavision.com](http://www.cellavision.com)  
[adele.horn@cellavision.com](mailto:adele.horn@cellavision.com)

## About Us

---

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 13 local market support organizations covering more than 40 countries. In 2022, sales were SEK 639 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at [www.cellavision.com](http://www.cellavision.com)

*This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-06 07:00 CET.*

## Attachments

---

[CellaVision and Sysmex Sign Strategic Alliance Agreement](#)